In other murine models, the association of KRAS mutations with other mutations such as LKB1 or PTEN, in the absence of GNAS mutations, made it possible to induce the development of IPMN-like lesions. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.